Literature DB >> 10688250

Identification of uridine diphosphate glucuronosyltransferases involved in the metabolism and clearance of mycophenolic acid.

P I Mackenzie1.   

Abstract

Mycophenolic acid, the active metabolite of the immunosuppressant and antiproliferative agent, mycophenolate mofetil, is primarily metabolized by glucuronidation to the inactive 7-O-glucuronide. Although the uridine diphosphate (UDP) 7-O-glucuronide is the principal excretion product of this drug, carboxyl-linked glucuronides have also been detected in vitro and in vivo. To identify human UDP glucuronosyltransferases that are active in the glucuronidation of mycophenolic acid, cDNAs encoding individual UDP glucuronosyltransferase forms have been expressed in cell culture, and the capacity of the expressed enzymes to use mycophenolic acid as a substrate has been assessed. Two UDP glucuronosyltransferase forms, UGT1A8 and UGT1A10, were active in the glucuronidation of mycophenolic acid. Both enzymes are predominantly expressed in the gastrointestinal tract and hence, may play a role in the metabolism of mycophenolic acid in the gastrointestinal tract and in the acquisition of resistance to the mito-inhibitory effects of this drug in cultured human colorectal carcinoma cell lines. The identities of the UDP glucuronosyltransferase forms that are mainly responsible for the glucuronidation of mycophenolic acid in the liver and kidney remain unknown; however, UGT1A9 may be important in this respect as the cDNA-expressed enzyme has some capacity to glucuronidate mycophenolic acid. Other UGT1A forms in the liver and kidney (UGT1A1, UGT1A3, UGT1A4, and UGT1A6) were inactive toward mycophenolic acid.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10688250     DOI: 10.1097/00007691-200002000-00002

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  15 in total

Review 1.  First-pass metabolism via UDP-glucuronosyltransferase: a barrier to oral bioavailability of phenolics.

Authors:  Baojian Wu; Kaustubh Kulkarni; Sumit Basu; Shuxing Zhang; Ming Hu
Journal:  J Pharm Sci       Date:  2011-04-11       Impact factor: 3.534

Review 2.  The influence of pharmacogenetics and cofactors on clinical outcomes in kidney transplantation.

Authors:  Nicolas Picard; Pierre Marquet
Journal:  Expert Opin Drug Metab Toxicol       Date:  2011-03-25       Impact factor: 4.481

3.  Regulation profile of phosphatidylcholines (PCs) and lysophosphatidylcholines (LPCs) components towards UDP-glucuronosyltransferases (UGTs) isoforms.

Authors:  Xin Gao; Hengyan Qu; Chun-Zhi Ai; Yun-Feng Cao; Ting Huang; Jian-Xing Chen; Jia Zeng; Xiao-Yu Sun; Mo Hong; Frank J Gonzalez; Zeyuan Liu; Zhong-Ze Fang
Journal:  Xenobiotica       Date:  2014-09-26       Impact factor: 1.908

4.  Polymorphisms of UGT1A9 and UGT2B7 influence the pharmacokinetics of mycophenolic acid after a single oral dose in healthy Chinese volunteers.

Authors:  Dong Guo; Liang-Fang Pang; Yang Han; Hong Yang; Guo Wang; Zhi-Rong Tan; Wei Zhang; Hong-Hao Zhou
Journal:  Eur J Clin Pharmacol       Date:  2012-10-10       Impact factor: 2.953

5.  Diabetes mellitus reduces activity of human UDP-glucuronosyltransferase 2B7 in liver and kidney leading to decreased formation of mycophenolic acid acyl-glucuronide metabolite.

Authors:  Miroslav Dostalek; Michael H Court; Suwagmani Hazarika; Fatemeh Akhlaghi
Journal:  Drug Metab Dispos       Date:  2010-12-01       Impact factor: 3.922

6.  The glucuronidation of mycophenolic acid by human liver, kidney and jejunum microsomes.

Authors:  K Bowalgaha; J O Miners
Journal:  Br J Clin Pharmacol       Date:  2001-11       Impact factor: 4.335

7.  Glucuronide and glucoside conjugation of mycophenolic acid by human liver, kidney and intestinal microsomes.

Authors:  M Shipkova; C P Strassburg; F Braun; F Streit; H J Gröne; V W Armstrong; R H Tukey; M Oellerich; E Wieland
Journal:  Br J Pharmacol       Date:  2001-03       Impact factor: 8.739

Review 8.  The evolution of population pharmacokinetic models to describe the enterohepatic recycling of mycophenolic acid in solid organ transplantation and autoimmune disease.

Authors:  Catherine M T Sherwin; Tsuyoshi Fukuda; Hermine I Brunner; Jens Goebel; Alexander A Vinks
Journal:  Clin Pharmacokinet       Date:  2011-01       Impact factor: 6.447

9.  Population Pharmacokinetics of Mycophenolic Acid Co-Administered with Tacrolimus in Corticosteroid-Free Adult Kidney Transplant Patients.

Authors:  Yan Rong; Patrick Mayo; Mary H H Ensom; Tony K L Kiang
Journal:  Clin Pharmacokinet       Date:  2019-11       Impact factor: 6.447

10.  Targeted inhibition of glucuronidation markedly improves drug efficacy in mice - a model.

Authors:  Nikhil K Basu; Labanyamoy Kole; Mousumi Basu; Antony F McDonagh; Ida S Owens
Journal:  Biochem Biophys Res Commun       Date:  2007-06-14       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.